Lexeo reports positive interim data for LX2020 in PKP2-ACM
The company looks forward to continuing to advance the program for patients and families affected by the disease.
See the latest news and media coverage for Lexeo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage genetic medicine company focused on cardiovascular and neurological diseases
lexeotx.comLast updated
In short: Lexeo reported positive interim LX2020 data, including an 80% reduction in arrhythmia burden.
The company looks forward to continuing to advance the program for patients and families affected by the disease.
High-dose cohorts showed 80% mean NSVT reduction; FDA is open to NSVT as a primary endpoint, and cash runway extends into 2028.
It adds four Friedreich ataxia programs and three research agreements, while continuing the SUNRISE-FA 2 pivotal study of LX2006.
Net loss was $25.9 million, cash of $234.2 million funds operations into 2028, and LX2020 received FDA RMAT designation.
Lexeo Therapeutics stock surged 23.7% in pre-open trading after the company released positive interim data from its HEROIC-PKP2 Phase I/II clinical trial of LX2020, a...
On Monday, Lexeo Therapeutics Inc. (NASDAQ:LXEO) announced positive interim results from its ongoing phase 1/2 HEROIC-PKP2 clinical trial...
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE)-- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with...
Lexeo Therapeutics (LXEO) stock rises as the FDA supports a potential accelerated approval pathway for LX2006, its treatment for Friedreich ataxia. Read more here.
Track Lexeo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lexeo and other trending companies.